WHO Launches Clinical Trial for New Ebola Treatment in DR Congo

The World Health Organization (WHO) has initiated a crucial clinical trial in the Democratic Republic of Congo to evaluate a new treatment for Ebola. This development offers a potential new weapon in the fight against the deadly filovirus.

The trial, officially known as the Platform Adaptive Randomised Trial for New and Repurposed Filovirus TreatmentS (PARTNERS), is designed to rigorously assess the efficacy of experimental and existing medications against filovirus infections. By testing both new and repurposed drugs, the WHO aims to expedite the availability of effective treatments.

Patient enrollment for the PARTNERS trial commenced on Thursday, marking a significant step forward in the ongoing efforts to combat Ebola outbreaks. The WHO's statement highlighted the commencement of this trial, underscoring the organization's commitment to advancing medical interventions and protecting public health in affected regions.

“

The trial, known as the Platform Adaptive Randomised Trial for New and Repurposed Filovirus TreatmentS (PARTNERS), began enrolling patients on Thursday, WHO said in a statement.